Michele Texter

The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ace inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function

Bertram Pitt, Blair J. O’Neill, Robert Feldman et al. · The American Journal of Cardiology · 2001 · 230 citations

Medicine, Cardiology, Pharmacology +13

Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of <i>Staphylococcus aureus</i> Bacteremia

J. John Weems, James P. Steinberg, Scott G. Filler et al. · Antimicrobial Agents and Chemotherapy · 2006 · 155 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Rationale and Design of the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study11See Appendix Afor the list of participants in the MIRACL study. That Evaluates Atorvastatin in Unstable Angina Pectoris and in Non–Q-Wave Acute Myocardial Infarction

Gregory G. Schwartz, Michael F. Oliver, Michael Ezekowitz et al. · The American Journal of Cardiology · 1998 · 89 citations

Medicine, Cardiology, Pharmacology +17

Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial

Alan Kivitz, Joy Schechtman, Michele Texter et al. · The Journal of Rheumatology · 2014 · 78 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +17

The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention

Michele Texter, Robert S. Lees, Bertram Pitt et al. · Cardiovascular Drugs and Therapy · 1993 · 39 citations · Full text

Medicine, Cardiology, Pharmacology +16